HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
Benzinga Newsdesk 12 hours ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.
